对老年患有阿尔茨海默氏症的成年人中跌倒风险的元分析
Sara Mahmoudzadeh Khalili1, Caroline Simpkins1, Feng Yang1
1Department of Kinesiology and Health, Georgia State University, Atlanta, GA, USA.
Journal of the American Medical Directors Association
|February 20, 2024
概括
患有阿尔茨海默氏病 (AD) 的老年人有较高的跌倒风险,每年患病率为44.27%. 这一元分析量化了秋季指标,强调了在AD研究中需要标准化报告的必要性.
科学领域:
- 老年学是指老年学的学科.
- 神经退行性疾病 神经退行性疾病
- 公共卫生 公共卫生
背景情况:
- 跌倒是老年人受伤的主要原因.
- 众所周知,阿尔茨海默病 (AD) 增加了跌倒风险,但报告的发病率有很大差异.
- 对于干预策略来说,了解AD中确切的跌倒风险至关重要.
研究的目的:
- 系统地审查和综合现有关于阿尔茨海默病 (AD) 患者跌倒风险的文献.
- 为患有AD的人提供与跌倒相关指标的全面摘要.
- 为了解决该人口中报告的跌倒风险的广泛差异.
主要方法:
- 进行了一项元分析.
- 从31项涉及4654名被诊断患有AD的老年人研究中综合了数据.
- 使用随机效应模型分析了跌倒的流行率,平均跌倒数,反复跌倒率和受伤跌倒率.
主要成果:
- 在阿尔茨海默氏症患者中,综合的年度跌倒患病率为44.27%.
- 每年平均每人跌倒次数为1.30.
- 复发性摔倒的年率为42.08%,受伤摔倒的年率为45.0%.
结论:
- 与认知健康的老年人相比,患有阿尔茨海默症的个体的跌倒风险明显更高.
- 合成的跌倒指标提供了更清晰的了解,在AD人群下降风险负担.
- 在AD中报告跌倒数据的标准化方法对于未来的研究和临床实践至关重要.
更多相关视频
04:13Using a Real-Time Locating System to Measure Walking Activity Associated with Wandering Behaviors Among Institutionalized Older Adults
Published on: February 8, 2019
6.8K
09:19Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
Published on: December 9, 2014
25.6K
相关概念视频
01:26Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189